Research analyst, medium-term horizon, biotech, small-cap

Ranbaxy Receives Paragraph IV Certification On Absorica, Panic Ensues

On September 19, 2013, Cipher Pharmaceuticals (CPHMF.PK) (DND.TO) announced that U.S. sales and distribution partner for Absorica, Ranbaxy Laboratories (OTC:RBXZF), has received a Paragraph IV Certification Notice of filing from Watson Laboratories, a division of Actavis plc (ACT), of an abbreviated new drug application (NASDAQ:ANDA) for a generic version of Absorica (CIP-isotretinoin capsules). Ranbaxy and Cipher intend to vigorously defend Absorica's intellectual property rights and pursue all available legal and regulatory pathways in defense of the product. But before we get into the details of the filing and how it impacts Cipher's valuation, investors may be curious - What exactly is a Paragraph IV Certification anyway?

A Little Background On ANDA's, Paragraph IV Challenges, and Hatch-Waxman...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details